Researchers Identify Prevalence Of KRAS G12C Mutation Across Tumor Types, Race, And Sex

The ASCO Post (1/20, Stenger) reports researchers “identified the prevalence of the formerly ‘undruggable’ KRAS G12C mutation across tumor types, race, and sex,” according to a letter to the editor published in the New England Journal of Medicine.